12 slides from Dr. Reddy's Laboratories's earnings presentation, Jul 28, 2022
Slide 1: Financial Results Q1 FY23
Financial Results Q1 FY23 July 28th, 2022 1 | July 28th, 2022 | Q1 FY23 Press Meet | As per consolidated financial statements under IFRS
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Q1 FY23 - Financial Highlights
Q1 FY23 - Financial Highlights Rs. Cr A quarter with strong growth in profits Q1 FY23 YoY Gr% QoQ Gr% Revenues 5,215 6% (4)% EBITDA 1,779 75% 37% PBT 1,466 97% 490% PAT 1,188 108% 1,257% 3 | July 28th, 2022 | Q1 FY23 Press Meet | As per consolidated financial statements under IFRS
Slide 4: Focusing on productivity while continuing to invest for growth
Focusing on productivity while continuing to invest for growth Rs. Cr Gross margin SG&A Expenses R&D Expenses YoY Inc 3% QoQ Dc -1% YoY Dc -5% QoQ Gr 0% 52.2% 52.9% 1,505 1,567 1,549 49.9% 453 433 433 % to 30.6% 28.8% 29.7% % to 9.2% 8.0% 8.3% Sales Sales Q1 Q4 Q1 Q1 Q4 Q1 Q1 Q4 Q1 FY22 FY22 FY23 FY
Slide 5: North America – Strong launch momentum continues
North America –Strong launch momentum continues | Incremental competition in a few of our key assets Revenues Q1 FY23 Rs. 1,782 cr Strong launch momentum continues - Launched Six products in US and one YoY Gr QoQ Dc in Canada +2% -11% Incremental competition seen in few key assets viz. gSuboxone
Slide 6: India – Healthy double digit growth
India – Healthy double digit growth Revenues Divested few of non-core brands allowing us to focus on our core brands Q1 FY23 Rs. 1,334 cr Healthy double digit growth adjusted for divestments in current quarter and YoY Gr QoQ Gr +26% +38% the covid product sales during Q1 FY22 Launched 5 new br
Slide 7: Emerging Markets – Healthy growth adjusted for covid product sales
Emerging Markets – Healthy growth adjusted for covid product sales in last year Revenues ₹ Cr Q1 FY23 Rs. 903 cr Region Q1 FY23 YoY Gr QoQ Gr Russia 321 -9% -53% YoY Dc QoQ Dc CISR 192 33% -16% -1% -25% RoW 390 -6% 36% EM 903 -1% -25% Decline due to: - Higher base effect: Covid product sales in Q1
Slide 8: Europe – Double digit growth in constant currency
Europe – Double digit growth in constant currency Revenues ₹ Cr Q1 FY23 Rs. 414 cr Region Q1 FY23 YoY Gr QoQ Gr Germany 221 -1% -17% YoY Gr QoQ Dc UK/OL 107 -8% 3% 4% -7% France, Italy, Spain & others 86 44% 17% Europe 414 4% -7% Base business: Good traction in volume, offset by price erosion Go
Slide 9: PSAI – Business grew adjusted for covid product sales
PSAI – Business grew adjusted for covid product sales in last year Revenues Decline seen on account of higher base due to covid product sales in last year Q1 FY23 Rs. 709 cr New product sales contribution continues in-line with the trend YoY Dc QoQ Dc -6% -6% Remains a key business for us for
Slide 10: R&D, Capex & Cash flows
R&D, Capex & Cash flows R&D expenses (Rs. Cr) Capex (Rs. Cr) % to sales 10.1% 8.8% 8.7% 8.2% 8.3% 1,561 1,541 1,654 1,748 1,466 974 696 433 485 331 FY19 FY20 FY21 FY22 Q1 FY23 FY19 FY20 FY21 FY22 Q1 FY23 Free cash flow (Rs. Cr) Net Debt / Equity 0.09 2,165 2,313 2,464 1,191 277 -0.03 -0.04 -0.08 -0.
Slide 11: Key Priorities
Key Priorities Diversified business model with broad based growth levers Strengthen Invest in new Build robust capabilities – avenues product people, digital (Horizon 2) of pipelines and processes growth Drive productivity Integrate ESG improvement into business 11 | July 28th, 2022 | Q1 FY23 Press
Slide 12: Thank You
THANK YOU 12 | July 28th, 2022 | Q1 FY23 Press Meet | As per consolidated financial Classification statements under IFRS | PUBLIC